Annandale, VA; October 31, 2020
Pfizer CEO Thanks Clinical Alliance for Research and Education – Infectious Diseases (CARE-ID) for Vaccine Study Partnership
As CARE-ID has reached its key milestone of allocated enrollees in this collaboration, the Pfizer CEO expressed his appreciation directly to the principal investigator and his team.
“On behalf of Pfizer and our leadership, I would like to personally thank you and your team[s] for your exceptional partnership over the last several months. This year has been unlike any we have ever experienced, as the COVID-19 pandemic continues to place great medical, social and economic burdens on the world. Whether you are in the United States [or other countries around the globe], we are all united in our commitment to determining whether we have a safe and effective vaccine candidate that can protect our communities from COVID-19 infection. Each of you has played an indispensable and extraordinary role in our quest to conquer this disease, and for that, we are profoundly grateful…”